TIA Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about TIA clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 447 trials

Recruiting
Phase 3

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225
Recruiting
Phase 3

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Eyelid Squamous Cell Carcinoma+17 more
National Cancer Institute (NCI)420 enrolled192 locationsNCT06568172
Recruiting
Phase 1

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

Metastatic SarcomaMetastatic LeiomyosarcomaUnresectable Leiomyosarcoma+9 more
National Cancer Institute (NCI)30 enrolled16 locationsNCT05711615
Recruiting
Phase 2

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Recurrent Endometrial CarcinomaEndometrial AdenocarcinomaEndometrial Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)81 enrolled136 locationsNCT05112601
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Metastatic Soft Tissue SarcomaMetastatic LeiomyosarcomaAdvanced Soft Tissue Sarcoma+5 more
National Cancer Institute (NCI)74 enrolled1 locationNCT06498648
Recruiting
Phase 3

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Metastatic Dedifferentiated LiposarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+3 more
National Cancer Institute (NCI)365 enrolled246 locationsNCT06422806
Recruiting
Phase 2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8Metastatic Prostate Small Cell Neuroendocrine CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation+1 more
National Cancer Institute (NCI)30 enrolled13 locationsNCT05691465
Recruiting
Not Applicable

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

HypertensionHypertension, SystolicHypertension,Essential
Orchestra BioMed, Inc500 enrolled98 locationsNCT06059638
Recruiting
Not Applicable

Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care

DepressionAnxietyPsychosis+1 more
Brigham and Women's Hospital45 enrolled3 locationsNCT07364825
Recruiting

Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study

Diabete Type 2Alzheimer Dementia (AD)
Rigshospitalet, Denmark60 enrolled1 locationNCT07482072
Recruiting
Phase 1Phase 2

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

LiposarcomaDedifferentiated LiposarcomaPleomorphic Liposarcoma+6 more
Memorial Sloan Kettering Cancer Center54 enrolled7 locationsNCT06843967
Recruiting
Phase 1

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Multiple System AtrophyParkinson DiseaseDementia With Lewy Bodies+2 more
Daniel Claassen40 enrolled1 locationNCT04246437
Recruiting
Not Applicable

EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))

Rheumatoid ArthritisOsteoarthritisTraumatic Arthritis+3 more
DePuy Orthopaedics118 enrolled5 locationsNCT06631638
Recruiting
Phase 2

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Alzheimer DementiaLate Onset Alzheimer DiseaseNeurodegenerative Diseases
University of Arizona100 enrolled10 locationsNCT04838301
Recruiting
Not Applicable

Social-cognitive Functioning: Validation of a New Neuropsychological Test

Frontotemporal Degeneration(FTD)Alzheimer's Disease(AD)Lewy Body Dementia (LBD)
Assistance Publique - Hôpitaux de Paris120 enrolled1 locationNCT05558709
Recruiting
Phase 2

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Acute Myeloid LeukemiaMyelodysplastic SyndromeMyeloproliferative Neoplasm+6 more
University of Washington25 enrolled1 locationNCT04282187
Recruiting

Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

Movement DisordersParkinson DiseaseDystonia+1 more
Boston Scientific Corporation200 enrolled4 locationsNCT06553625
Recruiting
Not Applicable

Dementia Caregivers' Link to Assistance and Resources

DementiaAlzheimer Disease or Associated Disorder
Visiting Nurse Service of New York200 enrolled1 locationNCT06860035
Recruiting
Phase 3

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

DementiaBrain DiseasesCentral Nervous System Diseases+6 more
Eli Lilly and Company1,500 enrolled141 locationsNCT05508789
Recruiting
Not Applicable

Investigating Subcortical Contributions to Speech Sequencing in Deep Brain Stimulator Recipients

Parkinson's Disease (PD)Essential Tremor
Boston University Charles River Campus80 enrolled2 locationsNCT07455760